10-KPeriod: FY2025

Medtronic plc Annual Report, Year Ended Apr 25, 2025

Filed June 20, 2025For Securities:MDT

Summary

Medtronic plc (MDT) reported its fiscal year 2025 results, demonstrating continued growth across its diverse medical technology portfolios. The company generated total net sales of $33.5 billion, a 4% increase year-over-year, driven by strong performance in the Cardiovascular and Neuroscience segments, with notable contributions from Cardiac Ablation Solutions, TAVR, Neuromodulation, and Spine products. The Diabetes Operating Unit also saw significant growth, albeit with plans for a future separation into an independent company. Financially, Medtronic maintained a strong liquidity position with $7.0 billion in operating cash flow and $5.2 billion in free cash flow. The company continued its commitment to shareholder returns through dividends and share repurchases, underscoring a stable financial footing. While facing some headwinds such as potential tariff impacts and ongoing litigation, Medtronic's strategic focus on innovation, patient outcomes, and leveraging technology like AI positions it for sustained growth in the dynamic healthcare landscape.

Financial Highlights

55 data points
Beta

Revenue

$33.54B

65.3% Gross Margin

Net Income

$4.69B

14.0% Net Margin

EPS (Diluted)

$3.61

Total Assets

$91.68B

Cash & Equivalents

$2.22B

Free Cash Flow

$5.18B

Financial Statements
Beta
Revenue$33.54B
Cost of Revenue$11.63B
Gross Profit$21.91B
SG&A Expenses$10.85B
Operating Income$5.96B
Net Income$4.69B
EPS (Basic)$3.63
EPS (Diluted)$3.61
Shares Outstanding (Basic)1.29B
Shares Outstanding (Diluted)1.29B

Key Highlights

  • 1Total net sales reached $33.5 billion, a 4% increase from the prior fiscal year, driven by broad-based growth across segments.
  • 2The Cardiovascular Portfolio grew 5% to $12.5 billion, with strong performance in Cardiac Rhythm & Heart Failure and Structural Heart & Aortic divisions.
  • 3The Neuroscience Portfolio saw a 5% increase in net sales to $9.8 billion, led by robust growth in Neuromodulation.
  • 4The Diabetes Operating Unit achieved an 11% increase in net sales to $2.8 billion, supported by strong adoption of its MiniMed 780G system, with plans for future separation.
  • 5Free cash flow remained strong at $5.2 billion, supporting the company's capital allocation priorities.
  • 6Medtronic repurchased $3.2 billion of its ordinary shares during fiscal year 2025 and announced an increase in its quarterly cash dividend, demonstrating a commitment to shareholder returns.
  • 7The company is actively managing currency exchange rate risks and interest rate risks through various financial instruments.

Frequently Asked Questions

Medtronic's revenue growth was primarily driven by its Cardiovascular and Neuroscience portfolios. Specific product lines that showed strong performance included Cardiac Ablation Solutions, Transcatheter Aortic Valve Replacement (TAVR) systems, Neuromodulation products like the Inceptiv spinal cord stimulator, and Spine technologies. The Diabetes segment also contributed significantly with the MiniMed 780G system.

Medtronic reported robust liquidity with $7.0 billion in operating cash flow and $5.2 billion in free cash flow for fiscal year 2025. The company has $2.2 billion in cash and cash equivalents and $6.7 billion in current investments. It maintains significant credit facilities and commercial paper programs to ensure financial flexibility and manage its capital structure effectively.

A significant strategic development is Medtronic's announced intention to separate its Diabetes business into a new, independent publicly traded company, expected to be completed within 18 months. This move aims to allow both Medtronic and the standalone diabetes business to better focus on their respective strategic priorities and growth opportunities.

Medtronic faces several risks and challenges, including intense competition, the need for continuous innovation, regulatory compliance in a complex global environment, potential impacts from international trade policies and tariffs (estimated at $200-$350 million in fiscal year 2026), and ongoing litigation, such as the hernia mesh and diabetes pump retainment ring cases. Cybersecurity threats and the integration of acquired businesses also remain key areas of focus.